Astra Zeneca's new heart drug Brilinta has been approved for use in the US by the US Food and Drug Administration (FDA).
Brilinta is a new oral medicine designed to prevent strokes and heart attacks in adult patients with acute coronary syndrome (ACS). It works by preventing the formation of new blood clots and maintaining blood flow in the body.
According to the American Heart Association, over one million Americans are hospitalised with ACS every year.
- The FDA approval of Brilinta is good news for patients in the United States and represents a significant milestone as we seek to help ensure ACS patients around the world have access to this innovative medicine, says Astra Zeneca CEO David Brennan in a press release.
Brilinta is now approved in 39 countries including the US, Brazil, Australia, and Canada under the trade name Brilinta and in the European Union under the trade name BriliqueTM. It is currently under review in an additional 45 countries including Russia, India and China.